Zosano Pharma (NASDAQ:ZSAN) reported quarterly losses of $(0.07) per share. This is a 36.36 percent increase over losses of $(0.11) per share from the same period last year.
Company integration and new efficiencies expected to generate cost structure improvements of greater than 25% beginning in Q4 2022 compared year-over-year with Q4 2021
mCloud exits